| Project/Area Number |
20590992
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | Gifu University |
|---|
Principal Investigator |
KIMURA Akio Gifu University, 医学部附属病院, 助教 (00362161)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
INUZUKA Takashi 岐阜大学, 医学系研究科, 教授 (50184734)
HOZUMI Isao 岐阜大学, 医学系研究科, 准教授 (20242430)
TANAKA Yuji 岐阜大学, 医学系研究科, 助教 (70377654)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2009: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2008: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Keywords | 脳・神経 / 免疫学 / autoantibody / Heat shock protein 70 / multiple sclerosis (MS) / proteome / Phoshoglyceate mutase 1(PGAMI) / Stress-70 protein(mtHSP70) / 多発性硬化症 / 視神経脊髄炎 / 自己抗体 / Phosphoglycerate mutase 1 / stress 70 protein / 通常型多発性硬化症 / 75 kDa glucose-regulated protein |
|---|
| Research Abstract |
We identified the autoantibody against Phosphoglycerate mutase 1 (PGAM 1) and mitochondrial heat shock protein 70 (mtHSP70) in serum from multiple sclerosis (MS) patients by immunoproteomic approach. We tested more samples by one-dimensional immunoblotting of human recombinant PGAM1 and mtHSP70. The prevalence of the anti-PGAM 1 antibody is significantly higher in serum from MS patients (81%) than in serum from other neurological diseases (ONDs) and healthy controls (HCs) (24～32%) (p<0.05). The prevalence of the anti-mtHSP70 antibody is also significantly higher in serum from MS patients (68%) than in serum from ONDs and HCs (20～30%) (p<0.05). We studied the clinical features and magnetic resonance imaging findings of MS patients with these antibodies. As a result, there were no significant differences between these antibodies-positive and -negative MS patients. Additionally, in our comprehensive analysis of the prevalence of both the anti-PGAM1 antibody and the anti-mtHSP70 antibody, the positivity rates of both these antibodies were significantly higher in serum from MS patients (57%) than in serum from patients with ONDs and HCs (0～16%) (p<0.05) ; moreover, the specificity of this combination assay was higher than that of the assay of only one antibody (57% sensitivity ; 93% specificity). Results of our study suggest that the combination of both these antibodies is useful for a more specific diagnosis of MS.
|
